Related Experiment Video
Updated: Feb 13, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Molecular and Cellular Determinants of Human Iron Overload Cardiomyopathy
Sayli S Modak1,2, Lina Greenberg1, W Tom Stump1
1Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Insights
Iron overload cardiomyopathy (IOC) damages heart function by affecting calcium transients and sarcomeric proteins. New engineered heart tissues model IOC, revealing iron
Area of Science:
- Cardiovascular Biology
- Stem Cell Technology
- Biomaterials Science
Background:
- Iron overload cardiomyopathy (IOC) results from excess systemic iron, causing cardiac dysfunction and arrhythmias.
- Studying IOC's cardiac-specific mechanisms is challenging due to multi-organ involvement.
- Existing models struggle to replicate the complex contractile and electrical aspects of IOC.
Purpose of the Study:
- To develop and utilize in vitro models to investigate the cellular and molecular mechanisms of human IOC.
- To probe the impact of iron overload on engineered human heart tissues.
- To identify specific pathways contributing to cardiac dysfunction in IOC.
Main Methods:
- Human engineered heart tissues (EHTs) composed of cardiomyocytes and cardiac fibroblasts were created.
- EHTs were subjected to iron overload conditions to mimic IOC.
- Cellular viability, reactive oxygen species (ROS) production, action potentials, calcium transients, and contractile force were assessed.
Main Results:
- Engineered heart tissues recapitulated key IOC features: reduced systolic/diastolic function and arrhythmias.
- Both cell types accumulated iron, but cardiomyocytes showed higher iron and ROS levels.
- Iron overload impaired calcium transient kinetics and amplitude, impacting contractility through oxidative damage and myosin inhibition.
Conclusions:
- Engineered heart tissues provide a faithful in vitro model for studying human IOC.
- Iron overload directly impairs cardiomyocyte calcium handling and contractile protein function.
- This research elucidates novel cellular and molecular mechanisms underlying IOC pathogenesis.
Abstract:
Iron overload cardiomyopathy (IOC) is a serious heart condition that is caused by elevated levels of systemic iron. IOC is characterized by both systolic and diastolic dysfunction as well as arrhythmias. It has been challenging to isolate the cardiac-specific cellular and molecular mechanisms driving IOC because the disease affects multiple interconnected organ systems. Here, we leverage stem cell technologies, cardiac tissue engineering, and protein reconstitution assays to model key aspects of human IOC in vitro and to probe the cellular and molecular mechanisms driving cardiac dysfunction. We demonstrate that human engineered heart tissues consisting of both cardiomyocytes and cardiac fibroblasts faithfully recapitulate key aspects of the human disease, including reduced systolic function, impaired diastolic function, and increased prevalence of arrhythmogenic events. We demonstrate that while both cardiomyocytes and cardiac fibroblasts show increased intracellular iron levels, leading to reduced viability, cardiomyocytes show higher levels of iron accumulation and higher levels of reactive oxygen species production. Moreover, we show that in a tissue, iron overload has little effect on the action potential kinetics; however, it directly impacts the amplitude and kinetics of the calcium transient, potentially driving arrhythmogenesis. Finally, we demonstrate that iron overload decreases force production, in part, through oxidative damage of sarcomeric proteins and direct iron-based inhibition of myosin. In summary, our results reveal new insights into the cellular and molecular mechanisms of human IOC pathogenesis, and they establish new in vitro models that can be harnessed to faithfully recapitulate key aspects of the human disease phenotype.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management

